Confinement et cannabis, cachez cette addiction que le gouvernement ne saurait voir Jean-Yves Nau — 2 avril 2020 à 7h00 SLATE http://www.slate.fr/story/189123/addictions-cannabis-confinement-coronavirus-deni-consequences-dependance Tabac, alcool et produits de vapotage n'ont heureusement pas été interdits. Mais il va falloir compter avec les multiples conséquences de la pénurie en cannabis. «Une dépendance grave à une substance licite vaut toujours mieux qu'une dépendance de moindre gravité à une substance interdite», déplore le Dr William Lowenstein, président de SOS Addictions. | Il croyait très bien faire. Lundi 23 mars, Ziad Khoury, préfet de l'Aisne, prenait un arrêté interdisant toutes les ventes d'alcool à emporter dans l'ensemble du département. Objectif: réduire les [...]
Lire la suiteThe Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis Samuel T. Wilkinson, M.D., Elizabeth D. Ballard, Ph.D., Michael H. Bloch, M.D., M.S., Sanjay J. Mathew, M.D., James W. Murrough, M.D., Ph.D., Adriana Feder, M.D., Peter Sos, M.D., Ph.D., Gang Wang, M.D., Carlos A. Zarate, Jr., M.D., Gerard Sanacora, M.D., Ph.D. American Journal of Psychiatry, 2018, 175, (2) 150–158. Doi : 10.1176/appi.ajp.2017.17040472 Objective : Suicide is a public health crisis with limited treatment options. The authors conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine [...]
Lire la suiteEndocannabinoids : A Promising Impact for Traumatic Brain Injury Lesley D. Schurman and Aron H. Lichtman Frontiers in Pharmacology, 2017. doi: 10.3389/fphar.2017.00069 The endogenous cannabinoid (endocannabinoid) system regulates a diverse array of physiological processes and unsurprisingly possesses considerable potential targets for the potential treatment of numerous disease states, including two receptors (i.e., CB1 and CB2 receptors) and enzymes regulating their endogenous ligands N-arachidonoylethanolamine (anandamide) and 2-arachidonyl glycerol (2-AG). Increases in brain levels of endocannabinoids to pathogenic events suggest this system plays a role in compensatory repair mechanisms. Traumatic brain injury (TBI) pathology remains mostly refractory to currently available drugs, perhaps due to its heterogeneous [...]
Lire la suiteCannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries A Retrospective Cohort Analysis Akash Goel, M.D., M.P.H., Brandon McGuinness, M.D.; Naheed K. Jivraj, M.B.B.S., M.Sc.; Duminda N. Wijeysundera, M.D., Ph.D.; Murray A. Mittleman, M.D., Dr.P.H.; Brian T. Bateman, M.D., M.Sc., Hance Clarke, M.D., Ph.D.; Lakshmi P. Kotra, B.Pharm. (Hons), Ph.D.; Karim S. Ladha, M.D., M.Sc. Anesthesiology, 2020, 132, (4), 625-635. Abstract and Introduction Background: Although cannabis is known to have cardiovascular and psychoactive effects, the implications of its use before surgery are currently unknown. The objective of the present study was to determine whether patients with an active cannabis use disorder have an elevated [...]
Lire la suiteShort- and Long-Term Effects of Cannabis on Headache and Migraine Carrie Cuttler, Alexander Spradlin, Michael J. Cleveland, and Rebecca M. Craft Journal of Pain, 2019. doi : 10.1016/j.jpain.2019.11.001 Highlights Headache and migraine ratings were reduced by nearly 50% after using cannabis Men reported larger reductions in headache after cannabis use than women Cannabis concentrates were related to larger reductions in headache than flower Evidence for tolerance to effects of cannabis on headache and migraine was detected Evidence for medication overuse headache was not detected Abstract Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to [...]
Lire la suiteCannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal Francisco Navarrete, Auxiliadora Aracil-Fernández and Jorge Manzanares British Journal of Pharmacology, 2018. Doi : 10.1111/bph.14226 BACKGROUND AND PURPOSE Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal. EXPERIMENTAL APPROACH Spontaneous cannabinoid withdrawal was evaluated 12 h after cessation of CP-55,940 treatment (0.5 mg·kg1 every 12 h, i.p.; 7 days) in C57BL/6J mice. The effects of CBD (5, 10 and 20 mg·kg1, i.p.) on withdrawal-related behavioural signs were evaluated by [...]
Lire la suiteCannabis is Not a Suitable Human Coronavirus Treatment Marc Moulin March 20, 2020 https://www.rxleaf.com/cannabis-not-good-human-coronavirus-treatment/ Using cannabis as a human coronavirus treatment may make symptoms worse. Cannabis is great for a lot of things. For example, many physical conditions see symptom abatement with cannabinoid treatment. Additionally, there is adequate, and in some cases, strong, scientific evidence to support consuming cannabis for therapeutic relief. Unfortunately, fighting off influenza-like viruses is not one of them. It’s important to note that there is absolutely no evidence to suggest that cannabis is an effective human coronavirus treatment. On the contrary, researchers from Michigan State University provide recent evidence to demonstrate potentially harmful [...]
Lire la suiteAddiction au cannabis, confinement et détention Jean Michel Delile, David Saint Vincent, Laurent Michel, Patrick Veteau Fédération Addiction, mars 2020 Cannabis et dépendance Longtemps, beaucoup ont pensé que le cannabis n’était pas une drogue (dangereuse), ou alors seulement une drogue « douce », au sens où il n’entrainait pas de syndrome physique de manque, à la différence de l’alcool, des opiacés ou des benzodiazépines… Il a fallu beaucoup de temps aux usagers et aux médecins pour réaliser que l’évidence de la souffrance des patients démontrait que la clef de l’addiction en tant que trouble était plus dans le désir/besoin irrépressible de consommer que dans [...]
Lire la suiteImmune Responses Regulated by Cannabidiol James M. Nichols and Barbara L.F. Kaplan Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2018.0073 Abstract Introduction : Cannabidiol (CBD) as Epidiolex (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and [...]
Lire la suiteLSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814 Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]
Lire la suite